COVID-19 tracker: CEPI discusses prep for next pandemic; Merck donates pills to Ukraine; Takeda’s Icatibant shows promise in labnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: NIH revs up study of allergic reactions to mRNA shotsnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Africa close to getting Pfizer’s pill; Moderna progresses omicron-specific booster trialnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: CDC study shows Pfizer shot ‘moderately’ effective versus omicron in kidsnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: China imposes new lockdowns amid surge in casesnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: AbbVie, Scripps Research to develop next-gen oral antiviralsnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Shionogi’s NIH-backed antiviral advances to phase 3news2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Biden taps new response coordinator; AZ’s Evusheld scores another green lightnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: WTO members to consider patent waiver deal; Ivermectin fails in Brazil studynews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: FDA summons expert meeting to discuss boosters, updating vaccinesnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
